Letter from the Editor

Dear Reader,

This year the AAN Annual Meeting took place in Boston, being no less than the 75^th edition of the yearly conference. Healthcare professionals from around the world came together to share their insights into the latest most cutting-edge science, covering a broad range of specialities, and providing the opportunity to connect with peers and friends. This review aims at providing summaries of the essentials of varied topics covered in the scientific sessions.

Particular highlights included the benefit of early intervention with disease-modifying treatments that was shown with the use of teriflunomide in patients with radiologically isolated syndrome. In adults with NMOSD, ravulizumab showed to lower the risk of relapse and had a good safety profile. And also in migraine research new developments were made, with atogepant effectively preventing treatment-resistant episodic migraine.

Please enjoy the reading.

Best wishes,

Hans-Peter Hartung

 

Biography

Prof. Hartung is currently Professor of Neurology at Heinrich-Heine-University Düsseldorf, Honorary Professor at Brain and Mind Center, University of Sydney, Visiting Professor at Medical University Vienna and Palacky University Olomouc. He was chairman of the Department of Neurology, Heinrich-Heine-University Düsseldorf from 2001-2020, director of the Center for Neurology and Neuropsychiatry from 2012-2020 and director of the Department of Conservative Medicine from 2012-2019.

Prof. Hartung’s clinical and translational research interests are in the field of basic and clinical neuroimmunology and in particular multiple sclerosis and immune neuropathies, development of new immunological, neuroprotective and neural repair promoting strategies. He has (co-)authored more than 950 articles in peer-reviewed journals and 100 book chapters. He has been involved as member of the Steering Committee in numerous international multicentre therapeutic phase 2 and 3 trials in multiple sclerosis, Guillain-Barré Syndrome and CIDP.

He was President of ECTRIMS and has served/ serves amongst others on the executive boards of the European Charcot Foundation, the European Neurological Society, and the International Multiple Sclerosis Cognition Society (IMSCOGS). He is/was also member of the Editorial Board of a number of international journals. Prof. Hartung is a Fellow of the AAN and EAN, and has been chair/ member of the management group of the EAN scientific panels on general neurology and multiple sclerosis. He is Corresponding and Honorary Fellow of several international societies.

Conflict of Interest Statement:

Hans-Peter Hartung has received fees for consulting, speaking, and serving on steering committees from Bayer Healthcare, Biogen, GeNeuro, MedImmune, Merck, Novartis, Opexa, Receptos Celgene, Roche, Sanofi Genzyme, CSL Behring, Octapharma, Teva, TG Therapeutics, and Viela Bio, with approval by the Rector of Heinrich-Heine University.



Posted on 26 June 202329 August 2023